Pennsylvania-based pharmaceutical company Certara has entered a partnership with Cloudscientific, aimed at bringing AI-powered drug discovery tools to the Chinese healthcare research community.
The collaboration allows Certara's D360 discovery informatics platform and Certara. AI software is to be distributed in China via Cloudscientific to advance discovery research for small molecules and biological candidates. The D360 platform provides access to data and integrated scientific intelligence.
Certara specializes in providing software products and technology-enabled services, including AI-powered solutions to the pharmaceutical sector. The company's focus is on model-informed drug development, offering solutions that predict pharmacokinetics and pharmacodynamics through software services such as Simcyp Simulator, which predicts drug behavior within the human body, and Phoenix WinNonlin IVIV for in vitro-in vivo correlation (IVIVC) studies.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.